Skip to main content
Premium Trial:

Request an Annual Quote

WaferGen Gains $10.7M in Stock After Reverse-Merger With Shell Company WaferGen Bio-systems

NEW YORK (GenomeWeb News) — WaferGen has completed a reverse merger with WaferGen Bio-systems, a Nevada-based shell company, under which WaferGen backed into WaferGen Bio-systems for an undisclosed sum.  
 
In connection with the deal, the new entity, WaferGen Bio-systems, received a private stock placement worth $10.7 million. The new company’s stock is trading on the Over-the-Counter Bulletin Board under the ticker name WGBS, and was up around 15 percent at $2.30 in afternoon trading today.   
 
WaferGen Bio said it plans to use the proceeds from the placement to pay for corporate infrastructure and product offerings, including development of its SmartChip system.
 
The company said it hopes to sell the system to pharmaceutical companies, academic institutions, and agricultural, environmental, and governmental agencies.
 
WaferGen Bio said it has retained WaferGen executives, including Alnoor Shivji, who is chairman and CEO of WaferGen, to serve in a senior management position.
 
The company has also named David Gelfand to the post of chief scientific officer.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.